U.S. will split profits with Tokyo from Japan-funded projects until $550 billion is recouped: Lutnick

Commerce Secretary Howard Lutnick detailed the U.S.-Japan tariff deal, revealing Japan will invest $550 billion into U.S.-based projects. Profits from these ventures will initially be split equally until Japan's investment is recouped, then shift to a 90/10 split favoring the U.S. This agreement, which also imposes 15% baseline tariffs on Japan, aims to bolster U.S. domestic manufacturing in strategic sectors like nuclear power and antibiotics, while providing Japan tariff benefits despite requiring significant initial borrowing. The deal's progression comes as broader U.S. tariff policies face legal challenges, including a Supreme Court review.

Analysis

The U.S.-Japan trade deal establishes a significant, long-term capital flow framework, where Japan will provide $550 billion for investment in U.S.-based projects in exchange for a modified tariff regime, including a 15% baseline. The financial structure is heavily weighted towards the U.S. in the long run; profits are split 50/50 only until Japan's initial investment is recouped, after which the U.S. will receive 90% of profits. This investment is explicitly intended to bolster U.S. domestic manufacturing capacity, with Commerce Secretary Howard Lutnick highlighting strategic priorities such as nuclear power plants and antibiotics. For Japan, the deal necessitates significant borrowing that will expand its national balance sheet, a move justified by the prospect of recouping the principal and securing lower tariff rates. However, a material legal risk overhangs the entire agreement, as the U.S. Supreme Court is set to review the legality of the administration's broader tariff policies, with oral arguments scheduled for November. An adverse ruling could undermine the legal foundation of this and other similar trade pacts.

Key Decisions for Investors

• Investors should identify and evaluate U.S. companies in the infrastructure, nuclear power, and pharmaceutical sectors, particularly those involved in antibiotics manufacturing, as they are positioned to be prime candidates for the $550 billion in project funding.
• The primary risk factor is legal and political; monitor developments related to the Supreme Court's hearing on tariff legality in November, as a ruling against the administration could invalidate the deal and create significant policy uncertainty.
• The requirement for Japan to significantly expand its balance sheet to fund the investment warrants a cautious watch on Japanese sovereign debt markets and the yen for potential signs of fiscal strain or currency volatility.